Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022349096> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W2022349096 endingPage "207" @default.
- W2022349096 startingPage "199" @default.
- W2022349096 abstract "In this study the direct actual costs associated with epilepsy-related health care, treatment with the novel antiepileptic drug vigabatrin (γ-vinyl GABA, GVG), epilepsy surgery evaluation (ESE) and epilepsy surgery were analysed in 52 patients with intractable partial epilepsy who were on a waiting-list for ESE while trying GVG. Sixty percent of the 52 patients obtained a reduction in seizure frequency of 50% or more with GVG. Of the twenty-one operated patients 57% became seizure free, 10% had more than 75%, had 50–75% and 29% had less than 50% reduction of seizure frequency. Of the 17 patients who did not go through ESE (the “GVG responders”), the corresponding outcome was 6%, 59%, 29% and 6%. For the 14 patients who were neither operated nor GVG responders, the outcome was 0%, 0%, 36% and 64%. The mean yearly costs (expressed in 1991 prices) of epilepsy-related health care including antiepileptic drug treatment was US $1594 the year before starting GVG therapy, and US $2959 the first year of GVG treatment including a mean yearly cost of GVG of US $1572. The mean total cost for ESE and surgery was US $46778 (N = 21), while the mean cost of ESE in patients evaluated but not accepted for surgery (N = 14) was US $24 054. Considering the costs for ESE and surgery in the whole patient series, the mean total cost of rendering one patient seizure free with surgery was US $110 000. Surgery is the most effective treatment option in selected cases of severe partial epilepsy. If its costs are distributed over the patient's expected lifetime, the yearly cost is comparable to the present yearly cost of medication with GVG.; However, since many patients achieve satisfactory seizure control with GVG, and considering the risks of surgery, we consider it a rational policy to let patients try this drug (or another of the new generation of antiepileptic drugs) before entering ESE." @default.
- W2022349096 created "2016-06-24" @default.
- W2022349096 creator A5022863718 @default.
- W2022349096 creator A5038089120 @default.
- W2022349096 creator A5061862920 @default.
- W2022349096 creator A5081367406 @default.
- W2022349096 creator A5087369432 @default.
- W2022349096 date "1996-11-01" @default.
- W2022349096 modified "2023-09-27" @default.
- W2022349096 title "Cost analysis of epilepsy surgery and of vigabatrin treatment in patients with refractory partial epilepsy" @default.
- W2022349096 cites W1964026305 @default.
- W2022349096 cites W1997318373 @default.
- W2022349096 cites W2007210344 @default.
- W2022349096 cites W2020803995 @default.
- W2022349096 cites W2075557562 @default.
- W2022349096 doi "https://doi.org/10.1016/s0920-1211(96)00027-7" @default.
- W2022349096 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8956917" @default.
- W2022349096 hasPublicationYear "1996" @default.
- W2022349096 type Work @default.
- W2022349096 sameAs 2022349096 @default.
- W2022349096 citedByCount "18" @default.
- W2022349096 countsByYear W20223490962016 @default.
- W2022349096 countsByYear W20223490962019 @default.
- W2022349096 countsByYear W20223490962020 @default.
- W2022349096 crossrefType "journal-article" @default.
- W2022349096 hasAuthorship W2022349096A5022863718 @default.
- W2022349096 hasAuthorship W2022349096A5038089120 @default.
- W2022349096 hasAuthorship W2022349096A5061862920 @default.
- W2022349096 hasAuthorship W2022349096A5081367406 @default.
- W2022349096 hasAuthorship W2022349096A5087369432 @default.
- W2022349096 hasConcept C118552586 @default.
- W2022349096 hasConcept C121332964 @default.
- W2022349096 hasConcept C141071460 @default.
- W2022349096 hasConcept C142424586 @default.
- W2022349096 hasConcept C2775858608 @default.
- W2022349096 hasConcept C2778186239 @default.
- W2022349096 hasConcept C2780803581 @default.
- W2022349096 hasConcept C2780837902 @default.
- W2022349096 hasConcept C3017633486 @default.
- W2022349096 hasConcept C3019985608 @default.
- W2022349096 hasConcept C42219234 @default.
- W2022349096 hasConcept C71924100 @default.
- W2022349096 hasConcept C87355193 @default.
- W2022349096 hasConceptScore W2022349096C118552586 @default.
- W2022349096 hasConceptScore W2022349096C121332964 @default.
- W2022349096 hasConceptScore W2022349096C141071460 @default.
- W2022349096 hasConceptScore W2022349096C142424586 @default.
- W2022349096 hasConceptScore W2022349096C2775858608 @default.
- W2022349096 hasConceptScore W2022349096C2778186239 @default.
- W2022349096 hasConceptScore W2022349096C2780803581 @default.
- W2022349096 hasConceptScore W2022349096C2780837902 @default.
- W2022349096 hasConceptScore W2022349096C3017633486 @default.
- W2022349096 hasConceptScore W2022349096C3019985608 @default.
- W2022349096 hasConceptScore W2022349096C42219234 @default.
- W2022349096 hasConceptScore W2022349096C71924100 @default.
- W2022349096 hasConceptScore W2022349096C87355193 @default.
- W2022349096 hasIssue "3" @default.
- W2022349096 hasLocation W20223490961 @default.
- W2022349096 hasLocation W20223490962 @default.
- W2022349096 hasOpenAccess W2022349096 @default.
- W2022349096 hasPrimaryLocation W20223490961 @default.
- W2022349096 hasRelatedWork W1458132091 @default.
- W2022349096 hasRelatedWork W1524257525 @default.
- W2022349096 hasRelatedWork W2025274009 @default.
- W2022349096 hasRelatedWork W2300658761 @default.
- W2022349096 hasRelatedWork W2314166922 @default.
- W2022349096 hasRelatedWork W2371867454 @default.
- W2022349096 hasRelatedWork W2406688026 @default.
- W2022349096 hasRelatedWork W2412853834 @default.
- W2022349096 hasRelatedWork W2436873138 @default.
- W2022349096 hasRelatedWork W4246006221 @default.
- W2022349096 hasVolume "25" @default.
- W2022349096 isParatext "false" @default.
- W2022349096 isRetracted "false" @default.
- W2022349096 magId "2022349096" @default.
- W2022349096 workType "article" @default.